Copyright
©The Author(s) 2018.
世界华人消化杂志. 2018-01-08; 26(1): 36-40
在线出版 2018-01-08. doi: 10.11569/wcjd.v26.i1.36
在线出版 2018-01-08. doi: 10.11569/wcjd.v26.i1.36
表2 两组患者治疗前后HCV DNA水平、肝功能改善及Child-Pugh评分的比较 (n = 20)
分组 | 时间 | ALT (U/L) | TBiL (μmol/L) | Alc (g/L) | Child-Pugh评分 | HCV DNA log10 (拷贝/mL) |
观察组 | 治疗前 | 122.4 ± 25.2 | 48.1 ± 14.9 | 30.1 ± 3.0 | 11.0 ± 1.29 | 6.20 ± 1.02 |
治疗4 wk后 | 111.9 ± 21.2a | 45.1 ± 15.1a | 30.0 ± 2.9 | 9.79 ± 2.5 | 5.20 ± 1.10 | |
治疗12 wk后 | 105.1 ± 17.9a | 40.9 ± 12.1a | 31.0 ± 1.9a | 10.3 ± 1.39 | 4.70 ± 1.47c | |
治疗24 wk后 | 88.7 ± 17.9ac | 37.0 ± 10.1ac | 32.0 ± 2.0ac | 9.7 ± 1.109c | 3.73 ± 1.23c | |
治疗48 wk后 | 48.1 ± 11.9ac | 30.0 ± 6.4ac | 35.2 ± 1.9ac | 7.4 ± 1.19ac | 3.32 ± 1.83c | |
对照组 | 治疗前 | 268.7 ± 43.0 | 71.0 ± 15.9 | 27.8 ± 1.49 | 10.2 ± 1.3 | 6.43 ± 1.0 |
治疗4 wk后 | 248.9 ± 31.9c | 67.0 ± 11.9 | 27.9 ± 2.49c | 10.79 ± 1.1 | 5.32 ± 4.01c | |
治疗12 wk后 | 218.9 ± 36.1 | 60.0 ± 14.1 | 27.9 ± 2.0 | 10.2 ± 1.0 | 4.90 ± 1.30 | |
治疗24 wk后 | 177.1 ± 42.0c | 53.0 ± 14.1c | 29.1 ± 2.0c | 9.3 ± 1.2c | 4.40 ± 1.23c | |
治疗48 wk后 | 106.3 ± 29.1c | 49.4 ± 18.2c | 31.2 ± 1.8c | 8.4 ± 1.2c | 3.79 ± 1.01c |
引文著录: 柴健, 韦学明, 张洁. 阿德福韦酯联合拉米夫定对乙型肝炎肝硬化失代偿期抗病毒效应的疗效对比. 世界华人消化杂志 2018; 26(1): 36-40